manilatimes2h
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced ...
Business Insider6h
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
“Based on the positive long-term data from the ORIGIN Phase 2b study presented at ASN Kidney Week, we’re excited to offer a clinical trial with atacicept to patients with nephrotic syndrome who have ...
Business Insider7h
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
We recently presented encouraging efficacy and safety data at ESMO on NUC-7738 plus pembrolizumab in patients with metastatic melanoma who were refractory or resistant to PD-1 inhibitors. We are ...
BioSpace8h
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
PharmiWeb14h
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical ... a patient population at high risk of relapse. Compelling 24.1-month median follow-up data presented showed that all ...